Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

US Patent 11548952 · Granted Jan 10, 2023

Estimated economic value: $12,595,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibodies against CD3 and CD202025
Bispecific antibodies against CD3 and CD202025
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leuk2024
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leuk2024
Bispecific antibody against CD3 and CD20 in combination therapy for treating dif2023
Bispecific antibody against CD3 and CD20 in combination therapy for treating dif2023
Methods of treating high risk multiple myeloma2023
Bispecific antibody against CD3 and CD20 in combination therapy for treating fol2023
Bispecific antibody against CD3 and CD20 in combination therapy for treating fol2023
Bispecific antibody against CD3 and CD20 in combination therapy for treating fol2022
Bispecific antibody against CD3 and CD20 in combination therapy for treating fol2022
Immune modulation and treatment of solid tumors with antibodies that specificall2021